Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effacts of alemtuzumab in patients with relapsed refractory multiple sclerosis: Three year Spanish Real-world study

Next Previous
Trial Profile

Effacts of alemtuzumab in patients with relapsed refractory multiple sclerosis: Three year Spanish Real-world study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LemVida

Most Recent Events

  • 27 Apr 2023 Status changed from recruiting to completed, according to Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 27 Apr 2023 Results assessing effectiveness of alemtuzumab on quality of life (QoL) of relapsing-remitting multiple sclerosis (RRMS) patients in a real-world setting, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 26 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top